Scandion Oncology announces modified timelines for clinical studies
Scandion Oncology A/S (“Scandion Oncology”) today announces modified timelines for the clinical Phase II colorectal cancer study and the dose range finding study for pancreatic cancer study.
Due to the experience of the past half year with COVID-19 pandemic there is a modification in the timelines of the clinical Phase II colorectal cancer study and the dose range finding study for pancreatic cancer study.
The timeline for the first part (dose range finding) of the ongoing colorectal cancer study that was expected to be finalized in Q4 2020, is now expected to be finalized in Q2 2021.
The timeline for the first part (dose range finding) of the upcoming pancreatic cancer study, that was expected to be initiated in Q2 2020, is now expected to be initiated in Q4 2020.
As previously announce (March 23, 2020) the COVID-19 pandemic has heavily affected the resources at the hospitals and health care systems - also in Denmark (https://www.spotlightstockmarket.com/en/market-overview/news/news-article/?id=56485&publisher=370).
Despite the COVID-19 situation, Scandion Oncology has been able to advance our clinical program with the above mentioned modifications in the timelines.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, CEO
Phone +45 28340871
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 7, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.